Loading
Giving extra chemotherapy after chemoradiation added side effects and no survival benefit, so timing matters: chemotherapy helps before radiation (INTERLACE), not after.
OUTBACK, also ANZGOG 0902 and GOG-0274, trial NCT01414608 sponsored by ANZGOG and NRG Oncology and published in Lancet Oncology in 2023, showed that giving four cycles of carboplatin and paclitaxel after chemoradiation for locally advanced cervical cancer adds side effects and no survival benefit. It randomised 919 patients, found no difference in overall or progression-free survival at five years, and 22 percent of the adjuvant arm never received the planned chemotherapy while severe toxicity rose sharply. OnCo links it to cervical cancer, modern radiotherapy, carboplatin, paclitaxel, NRG Oncology, the GOG Foundation, Linda Mileshkin and the pairing of induction chemotherapy before chemoradiation. Set beside INTERLACE, it shows that timing matters: chemotherapy helps before radiation, not after, and why that should be so is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Carboplatin and the tag failure.
Shares Cervical cancer and the tag failure.
Shares Paclitaxel / nab-paclitaxel and the tag failure.
Shares IMRT / IGRT (modern external beam) and the tag failure.
Shares IMRT / IGRT (modern external beam) and the tag failure.
Shares Induction chemotherapy → chemoradiation (locally advanced cervical cancer), Locally advanced cervical cancer, Paclitaxel / nab-paclitaxel, Cervical cancer.
Shares Locally advanced cervical cancer, Paclitaxel / nab-paclitaxel, Cervical cancer, Carboplatin.
Shares GOG Foundation, NRG Oncology, Paclitaxel / nab-paclitaxel, Carboplatin.